Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 6, 2022

Primary Completion Date

August 1, 2022

Study Completion Date

August 1, 2022

Conditions
Bullous Pemphigoid
Interventions
DRUG

nomacopan (rVA576)

Nomacopan an inhibitor of complement C5 and LTB4

OTHER

Placebo

Placebo

Trial Locations (12)

15213

UMPC Department of Dermatology, Pittsburgh

22391

MENSINGDERMA Research GmbH, Hamburg

24105

Universitätsklinikum Schleswig-Holstein, Kiel

27710

Duke Dermatology, Durham

45324

Wright State Physicians 725 University Blvd., Fairborn

46250

Dawes Fretzin Clinical Research Group LLC, Indianapolis

48103

David Fivenson MD PLC, Ann Arbor

60077

North Shore University Health System, Skokie

70112

Tulane University Health Sciences Center, Los Angeles

72076

Universitäts Hautklinik, Tübingen

9700RB

University Medical Center Groningen, Groningen

Unknown

Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AKARI Therapeutics

INDUSTRY